Q-omics provides the consensus-scored RAB32 profile across patient tissues and cancer cell-line models. RAB32 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, RAB32 is differentially expressed in 14, with the highest sampling consensus in HNSC. Additionally, RAB32 protein abundance shows 27,055 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight MESO, HNSC, and LSCC as cancer lineages where RAB32 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RAB32 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RAB32 survival associations across molecular data types. RAB32 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (1) and mass-spec protein abundance (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RAB32 RNA expression–survival associations across cancer types. High RAB32 expression shows unfavorable associations in MESO, LIHC, KICH, UCEC, HNSC and LGG. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for RAB32 RNA expression.
This table summarizes RAB32 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 9. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for RAB32. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RAB32 shows lower tumor expression in LUAD, LUSC and COAD and higher tumor expression in HNSC, KIRC and KIRP. The HNSC box plot shows higher RAB32 RNA expression in tumor versus normal tissue (log2 FC = +2.040, t-test p < 0.001).
This table shows molecular features associated with RAB32 in patient tissues and cancer cell lines. In patient samples, RAB32 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, RAB32 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in CNS and BONE.
